Do classical oestrogen markers predict for clinical response to endocrine therapy?
Open Access
- 20 December 2007
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 9 (S2), S19
- https://doi.org/10.1186/bcr1817
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Aromatase inhibitors—Gene discoveryThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Estrogen-Regulated Genes Predict Survival in Hormone Receptor–Positive Breast CancersJournal of Clinical Oncology, 2006
- Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozoleBritish Journal of Cancer, 2006
- Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumorsGenome Biology, 2006
- Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT TrialistsJournal of Clinical Oncology, 2005
- Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression ProfilingJournal of Clinical Oncology, 2005
- Profiling of Estrogen Up- and Down-Regulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell PhenotypeEndocrinology, 2003
- Development of cDNA microarray for expression profiling of estrogen-responsive genesJournal of Molecular Endocrinology, 2002
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001
- Effects of estrogen on global gene expression: identification of novel targets of estrogen action.2000